KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Operating Expenses: 2013-2024

Historic Other Operating Expenses for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Dec 2024 value amounting to $149.8 million.

  • Supernus Pharmaceuticals' Other Operating Expenses rose 20.07% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 1.86%. This contributed to the annual value of $149.8 million for FY2024, which is 18.97% down from last year.
  • Supernus Pharmaceuticals' Other Operating Expenses amounted to $149.8 million in FY2024, which was down 18.97% from $184.8 million recorded in FY2023.
  • Supernus Pharmaceuticals' Other Operating Expenses' 5-year high stood at $184.8 million during FY2023, with a 5-year trough of $70.1 million in FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Other Operating Expenses averaged around $168.0 million, with its median value being $169.3 million (2022).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Other Operating Expenses skyrocketed by 220.81% in 2020 and then decreased by 18.97% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Other Operating Expenses (Yearly) stood at $70.1 million in 2020, then skyrocketed by 40.62% to $98.5 million in 2021, then surged by 71.88% to $169.3 million in 2022, then increased by 9.15% to $184.8 million in 2023, then declined by 18.97% to $149.8 million in 2024.